<DOC>
	<DOC>NCT00105287</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl when used long-term to relieve breakthrough pain in opioid tolerant cancer patients.</brief_summary>
	<brief_title>Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Documented diagnosis of a malignant solid tumor or hematological malignancy causing cancer related pain Currently taking around the clock opioid therapy for pain Experience on average, 14 breakthrough pain episodes per day Opioid or fentanyl intolerance Sleep apnea or active brain metastases with increased intracranial pressure COPD (chronic obstructive pulmonary disease); cardiopulmonary disease; heart disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>cancer</keyword>
	<keyword>pain</keyword>
	<keyword>Breakthrough Pain in cancer patients</keyword>
</DOC>